Streetbeat News

Price Targets

PH

Keybanc analyst Jeffrey Hammond maintains an Overweight rating on Parker Hannifin (NYSE:PH) and raises the price target from $390 to $450.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:41 am

OMCL

Keybanc analyst Scott Schoenhaus maintains an Overweight rating on Omnicell (NASDAQ:OMCL) and raises the price target from $70 to $80.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:40 am

ITT

Keybanc analyst Jeffrey Hammond maintains an Overweight rating on ITT (NYSE:ITT) and raises the price target from $100 to $110.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:39 am

LPTX

Raymond James analyst Steven Seedhouse maintains an Outperform rating on Leap Therapeutics (NASDAQ:LPTX) and raises the price target from $17 to $18.5.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:38 am

HRI

Keybanc analyst Ken Newman has maintained an Overweight rating on Herc Hldgs (NYSE:HRI) and raised the price target from $150 to $170.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:37 am

CDNS

Keybanc analyst Jason Celino maintains an Overweight rating on Cadence Design Sys (NASDAQ:CDNS) and raises the price target from $235 to $265.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 8:36 am

BLDR

Builders FirstSource (NYSE:BLDR) has received mostly bullish analyst ratings in the last quarter, with an average 12-month price target of $135.2, a high of $175.00, and a low of $95.00. The average price target has increased by 17.31% over the past month. Analysts determine these ratings based on the company's predicted future earnings and the risk associated with its revenue streams.

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 9:01 pm

ELV

A significant amount of unusual options activity has been detected for Elevance Health (NYSE:ELV), with a majority of investors taking a bullish stance. The trades include 10 puts amounting to $327,672 and 13 calls amounting to $691,930. Whales have been targeting a price range from $370.0 to $490.0 for Elevance Health over the last 3 months. The current price of ELV is down -4.78% at $414.13, with RSI indicators suggesting the stock may be approaching oversold.

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 8:51 pm

ADT

Over the past 3 months, 4 analysts have published their opinion on ADT (NYSE:ADT) stock. The company has an average price target of $9.15, a decrease of 8.5% from the previous average price target of $10.00. Two analysts have given bullish ratings, while two have remained indifferent.

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 8:01 pm

ACVA

Over the past 3 months, 15 analysts have published their opinion on ACV Auctions (NASDAQ:ACVA) stock. The company has an average price target of $19.33, up by 19.76% from the previous average price target of $16.14. The majority of the ratings are bullish.

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 7:01 pm